Quantum-Si Pushes Proteus Launch to Q2 2027, Reduces Workforce by 20%, and Extends Cash Runway to Q4 2028
QSI sits 17% above its 52-week low of $0.69.
Summary
Quantum-Si reported Q2 revenue of $344,000, delayed its Proteus launch to Q2 2027, announced a 20% workforce reduction, and extended its cash runway into Q4 2028.
Key Events · Earnings and Guidance · QSI
-
Proteus Launch Delayed to Q2 2027
An integrated instrument design cycle for manufacturing readiness has been added, pushing the anticipated commercial launch from an unspecified earlier date to Q2 2027.
-
20% Workforce Reduction
A reduction in force of approximately 20% of headcount is expected to generate $12 million in annualized operating expense savings once fully implemented.
-
Cash Runway Extended to Q4 2028
With $169.9 million in cash, cash equivalents, and marketable securities as of June 30, 2026, existing capital is expected to fund operations into Q4 2028, extended from Q2 2028.
-
Q2 Revenue Down 42% Year-Over-Year
Revenue of $344,000 compared to $591,000 in Q2 2025 reflects the transition from Platinum to Proteus and lower instrument demand.
Analysis · QSI · Industrial Applications And Services
The Q2 results from Quantum-Si confirm a difficult transition period. Revenue fell 42% year-over-year to $344,000, and the company is delaying its flagship Proteus platform launch to Q2 2027 to complete an additional design cycle. A 20% workforce reduction and $12 million in annualized cost savings extend the cash runway into Q4 2028, but the delay means another year of minimal revenue and continued cash burn. The company also highlighted a $4 billion non-human proteomics market opportunity, which could expand the addressable market but remains unproven. With $169.9 million in cash and investments, there is breathing room, yet the stock trades at $0.81 and faces Nasdaq delisting risk after falling below $1.00.
At the time of this filing, QSI was trading at $0.81 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $172M. The 52-week trading range was $0.69 to $3.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.